The cytoskeleton in neurodegenerative diseases.
PDF (524K)
Journal: 2004/December - Journal of Pathology
ISSN: 0022-3417
Abstract:
Abundant abnormal aggregates of cytoskeletal proteins are neuropathological signatures of many neurodegenerative diseases that are broadly classified by filamentous aggregates of neuronal intermediate filament (IF) proteins, or by inclusions containing the microtubule-associated protein (MAP) tau. The discovery of mutations in neuronal IF and tau genes firmly establishes the importance of neuronal IF proteins and tau in the pathogenesis of neurodegenerative diseases. Multiple IF gene mutations are pathogenic for Charcot-Marie-Tooth (CMT) disease and amyotrophic lateral sclerosis (ALS)--in addition to those in the copper/zinc superoxide dismutase-1 (SOD1) gene. Tau gene mutations are pathogenic for frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), and tau polymorphisms are genetic risk factors for sporadic progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Thus, IF and tau abnormalities are linked directly to the aetiology and pathogenesis of neurodegenerative diseases. In vitro and transgenic animal models are being used to demonstrate that different mutations impair protein function, promote tau fibrilization, or perturb tau gene splicing, leading to aberrant and distinct tau aggregates. For recognition of these disorders at neuropathological examination, immunohistochemistry is needed, and this may be combined with biochemistry and molecular genetics to properly determine the nosology of a particular case. As reviewed here, the identification of molecular genetic defects and biochemical alterations in cytoskeletal proteins of human neurodegenerative diseases has facilitated experimental studies and will promote the development of assays of molecules which inhibit abnormal neuronal IF and tau protein inclusions.
Open in
PUBMED | DOI | PMC | Google Scholar | Wikipedia
Relations:
Content
Citations
(44)
References
(124)
Diseases
(3)
Chemicals
(2)
Organisms
(2)
Processes
(1)
Anatomy
(3)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
J Pathol 204(4): 438-449
PMID: 15495240

The cytoskeleton in neurodegenerative diseases

Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, and Institute on Aging, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-4283, USA
Correspondence to: Nigel J Cairns, Center for Neurodegenerative Disease Research, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Maloney Building, 3rd Floor, 3600 Spruce Street, Philadelphia, PA 19104, USA. ude.nnepu.dem.liam@snriac
Copyright notice

Abstract

Abundant abnormal aggregates of cytoskeletal proteins are neuropathological signatures of many neurodegenerative diseases that are broadly classified by filamentous aggregates of neuronal intermediate filament (IF) proteins, or by inclusions containing the microtubule-associated protein (MAP) tau. The discovery of mutations in neuronal IF and tau genes firmly establishes the importance of neuronal IF proteins and tau in the pathogenesis of neurodegenerative diseases. Multiple IF gene mutations are pathogenic for Charcot–Marie–Tooth (CMT) disease and amyotrophic lateral sclerosis (ALS) — in addition to those in the copper/zinc superoxide dismutase-1 (SOD1) gene. Tau gene mutations are pathogenic for frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), and tau polymorphisms are genetic risk factors for sporadic progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). Thus, IF and tau abnormalities are linked directly to the aetiology and pathogenesis of neurodegenerative diseases. In vitro and transgenic animal models are being used to demonstrate that different mutations impair protein function, promote tau fibrilization, or perturb tau gene splicing, leading to aberrant and distinct tau aggregates. For recognition of these disorders at neuropathological examination, immunohistochemistry is needed, and this may be combined with biochemistry and molecular genetics to properly determine the nosology of a particular case. As reviewed here, the identification of molecular genetic defects and biochemical alterations in cytoskeletal proteins of human neurodegenerative diseases has facilitated experimental studies and will promote the development of assays of molecules which inhibit abnormal neuronal IF and tau protein inclusions.

Keywords: neuronal intermediate filament, tau, cytoskeleton, mutation, neurodegenerative disease, peripheral neuropathy
Abstract

References

  • 1. Lee K, Cleveland DWNeuronal intermediate filaments. Annu Rev Neurosci. 1996;19:187–217.[PubMed][Google Scholar]
  • 2. Lee VM-Y, Goedert M, Trojanowski JQNeurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121–1159.[PubMed][Google Scholar]
  • 3. Goedert M, Spillantini MG, Serpell LC, et al From genetics to pathology: tau and alpha-synuclein assemblies in neurodegenerative diseases. Philos Trans R Soc London Ser B Biol Sci. 2001;356:213–227.[Google Scholar]
  • 4. Cleveland DW, Rothstein JDFrom Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3:55–56.[PubMed][Google Scholar]
  • 5. Al-Chalabi A, Miller CCJNeurofilaments and neurological disease. Bioessays. 2003;25:346–365.[PubMed][Google Scholar]
  • 6. Lariviere RC, Julien JPFunctions of intermediate filaments in neuronal development and disease. J Neurobiol. 2004;58:131–148.[PubMed][Google Scholar]
  • 7. Jordanova A, De Jonghe P, Boerkoel CF, et al Mutations in the neurofilament light chain gene (NEFL) cause early onset severe Charcot–Marie–Tooth disease. Brain. 2003;126:590–597.[PubMed][Google Scholar]
  • 8. De Jonghe P, Mersivanova I, Nelis E, et al Further evidence that neurofilament light chain gene mutations can cause Charcot–Marie–Tooth disease type 2E. Ann Neurol. 2001;49:245–249.[PubMed][Google Scholar]
  • 9. Yoshihara T, Yamamoto M, Hattori N, et al Identification of novel sequence variants in the neurofilament-light gene in a Japanese population: analysis of Charcot–Marie–Tooth disease patients and normal individuals. J Peripher Nerv Syst. 2002;7:221–224.[PubMed][Google Scholar]
  • 10. Georgiou DM, Zidar J, Korosec M, Middleton LT, Kyriakides T, Christodoulou KA novel NF-L mutation Pro22Ser is associated with CMT2 in a large Slovenian family. Neurogenetics. 2002;4:93–96.[PubMed][Google Scholar]
  • 11. Fabrizi GM, Cavallaro T, Angiari C, et al Giant axon and neurofilament accumulation in Charcot–Marie–Tooth disease type 2E. Neurology. 2004;62:1429–1431.[PubMed][Google Scholar]
  • 12. Mersiyanova IV, Perepelov AV, Polyakov AV, et al A new variant of Charcot–Marie–Tooth disease type 2 is probably the result of a mutation in the neurofilament-light gene. Am J Hum Genet. 2000;67:37–46.[Google Scholar]
  • 13. Zuchner S, Vorgerd M, Sindern E, Schroder JMThe novel neurofilament light (NEFL) mutation Glu397Lys is associated with a clinically and morphologically heterogeneous type of Charcot–Marie–Tooth neuropathy. Neuromuscul Disord. 2004;14:147–157.[PubMed][Google Scholar]
  • 14. Lavedan C, Buchholtz S, Nussbaum RL, Albin RL, Polymeropoulos MHA mutation in the human neurofilament M gene in Parkinson’s disease that suggests a role for the cytoskeleton in neuronal degeneration. Neurosci Lett. 2002;322:57–61.[PubMed][Google Scholar]
  • 15. Figlewicz DA, Krizus A, Martinoli MG, et al Variants of the heavy neurofilament subunit are associated with the development of amyotrophic lateral sclerosis. Hum Mol Genet. 1994;3:1757–1761.[PubMed][Google Scholar]
  • 16. Al-Chalabi A, Andersen PM, Nilsson P, et al Deletions of the heavy neurofilament subunit tail in amyotrophic lateral sclerosis. Hum Mol Genet. 1999;8:157–164.[PubMed][Google Scholar]
  • 17. Tomkins J, Usher P, Slade JY, et al Novel insertion in the KSP region of the neurofilament heavy gene in amyotrophic lateral sclerosis (ALS) Neuroreport. 1998;9:3967–3970.[PubMed][Google Scholar]
  • 18. Hayashi S, Toyoshima Y, Hasegawa M, et al Late-onset frontotemporal dementia with a novel exon 1 (Arg5His) tau gene mutation. Ann Neurol. 2002;51:525–530.[PubMed][Google Scholar]
  • 19. Poorkaj P, Muma NA, Zhukareva V, et al An R5L tau mutation in a subject with a progressive supranuclear palsy phenotype. Ann Neurol. 2002;52:511–516.[PubMed][Google Scholar]
  • 20. Pickering-Brown S, Baker M, Yen SH, et al Pick’s disease is associated with mutations in the tau gene. Ann Neurol. 2000;48:859–867.[PubMed][Google Scholar]
  • 21. Rizzini C, Goedert M, Hodges JR, et al Tau gene mutation K257T causes a tauopathy similar to Pick’s disease. J Neuropathol Exp Neurol. 2000;59:990–1001.[PubMed][Google Scholar]
  • 22. Reed LA, Wszolek ZK, Hutton MPhenotypic correlations in FTDP-17. Neurobiol Aging. 2001;22:89–107.[PubMed][Google Scholar]
  • 23. Kobayashi T, Ota S, Tanaka K, et al A novel L266V mutation of the tau gene causes frontotemporal dementia with a unique tau pathology. Ann Neurol. 2003;53:133–137.[PubMed][Google Scholar]
  • 24. Hutton M, Lendon CL, Rizzu P, et al Association of missense and 5′-splice-site mutations in tau with the inherited dementia FTDP-17. Nature. 1998;393:702–705.[PubMed][Google Scholar]
  • 25. Rizzu P, Van Swieten JC, Joosse M, et al High prevalence of mutations in the microtubule-associated protein tau in a population study of frontotemporal dementia in The Netherlands. Am J Hum Genet. 1999;64:414–421.[Google Scholar]
  • 26. Clark LN, Poorkaj P, Wszolek Z, et al Pathogenic implications of mutations in the tau gene in pallido-ponto-nigral degeneration and related neurodegenerative disorders linked to chromosome 17. Proc Natl Acad Sci U S A. 1998;95(13):13 103–13 107.[Google Scholar]
  • 27. D’Souza I, Poorkaj P, Hong M, et al Missense and silent tau gene mutations cause frontotemporal dementia with parkinsonism–chromosome 17 type, by affecting multiple alternative RNA splicing regulatory elements. Proc Natl Acad Sci U S A. 1999;96:5598–5603.[Google Scholar]
  • 28. Spillantini MG, Yoshida H, Rizzini C, et al A novel tau mutation (N296N) in familial dementia with swollen achromatic neurons and corticobasal inclusion bodies. Ann Neurol. 2000;48:939–943.[PubMed][Google Scholar]
  • 29. Iseki E, Matsumura T, Marui W, et al Familial frontotemporal dementia and parkinsonism with a novel N296H mutation in exon 10 of the tau gene and a widespread tau accumulation in glial cells. Acta Neuropathol. 2001;102:285–292.[PubMed][Google Scholar]
  • 30. Pastor P, Pastor E, Carnero C, et al Familial atypical progressive supranuclear palsy associated with homozygosity for the delN296 mutation in the tau gene. Ann Neurol. 2001;49:263–267.[PubMed][Google Scholar]
  • 31. Bugiani O, Murrell JR, Giaccone G, et al Frontotemporal dementia and corticobasal degeneration in a family with a P301S mutation in tau. J Neuropathol Exp Neurol. 1999;58:667–677.[PubMed][Google Scholar]
  • 32. Sperfeld AD, Collatz MB, Baier H, et al FTDP-17: an early-onset phenotype with parkinsonism and epileptic seizures caused by a novel mutation. Ann Neurol. 1999;46:708–715.[PubMed][Google Scholar]
  • 33. Hasegawa M, Smith MJ, Iijima M, Tabira T, Goedert MFTDP-17 mutations N279K and S305N in tau produce increased splicing of exon 10. FEBS Lett. 1999;443:93–96.[PubMed][Google Scholar]
  • 34. Iijima M, Tabira T, Poorkaj P, et al A distinct familial presenile dementia with a novel missense mutation in the tau gene. Neuroreport. 1999;10:497–501.[PubMed][Google Scholar]
  • 35. Stanford PM, Halliday GM, Brooks WS, et al Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene: expansion of the disease phenotype caused by tau gene mutations. Brain. 2000;123:880–893.[PubMed][Google Scholar]
  • 36. Spillantini MG, Bird TD, Ghetti BFrontotemporal dementia and parkinsonism linked to chromosome 17: a new group of tauopathies. Brain Pathol. 1998;8:387–402.[PubMed][Google Scholar]
  • 37. Miyamoto K, Kowalska A, Hasegawa M, et al Familial frontotemporal dementia and parkinsonism with a novel mutation at an intron 10 + 11-splice site in the tau gene. Ann Neurol. 2001;50:117–120.[PubMed][Google Scholar]
  • 38. Yasuda M, Takamatsu J, D’Souza I, et al A novel mutation at position +12 in the intron following exon 10 of the tau gene in familial frontotemporal dementia (FTD-Kumamoto) Ann Neurol. 2000;47:422–429.[PubMed][Google Scholar]
  • 39. Lantos PL, Cairns NJ, Khan MN, et al Neuropathologic variation in frontotemporal dementia due to the intronic tau 10 (+16) mutation. Neurology. 2002;58:1169–1175.[PubMed][Google Scholar]
  • 40. van Herpen E, Rosso SM, Serverijnen LA, et al Variable phenotypic expression and extensive tau pathology in two families with the novel tau mutation L315R. Ann Neurol. 2003;54:573–581.[PubMed][Google Scholar]
  • 41. Rosso SM, van Herpen E, Deelen W, et al A novel tau mutation, S320F, causes a tauopathy with inclusions similar to those in Pick’s disease. Ann Neurol. 2002;51:373–376.[PubMed][Google Scholar]
  • 42. Pickering-Brown SM, Baker M, Nonaka T, et al Frontotemporal dementia with Pick-type histology associated with Q336R mutation in the tau gene. Brain. 2004;127:1415–1426.[PubMed][Google Scholar]
  • 43. Poorkaj P, Bird TD, Wijsman E, et al Tau is a candidate gene for chromosome 17 frontotemporal dementia. Ann Neurol. 1998;43:815–825.[PubMed][Google Scholar]
  • 44. Lippa CF, Zhukareva V, Kawarai T, et al Frontotemporal dementia with novel tau pathology and a Glu342Val tau mutation. Ann Neurol. 2000;48:850–858.[PubMed][Google Scholar]
  • 45. Nicholl DJ, Greenstone MA, Clarke CE, et al An English kindred with a novel recessive tauopathy and respiratory failure. Ann Neurol. 2003;54:682–686.[PubMed][Google Scholar]
  • 46. Neumann M, Schulz-Schaeffer W, Crowther RA, et al Pick’s disease associated with the novel tau gene mutation K369I. Ann Neurol. 2001;50:503–513.[PubMed][Google Scholar]
  • 47. Murrell JR, Spillantini MG, Zolo P, et al Tau gene mutation G389R causes a tauopathy with abundant pick body-like inclusions and axonal deposits. J Neuropathol Exp Neurol. 1999;58:1207–1226.[PubMed][Google Scholar]
  • 48. Ching GY, Liem RKHStructure of the gene for the neuronal intermediate filament protein α-internexin and functional analysis of its promoter. J Biol Chem. 1991;266:19 459–19 468.[PubMed][Google Scholar]
  • 49. Schmidt ML, Carden MJ, Lee VM-Y, Trojanowski JQPhosphate dependent and independent neurofilament epitopes in the axonal swellings of patients with motor neuron disease and controls. Lab Invest. 1987;56:282–294.[PubMed][Google Scholar]
  • 50. Ching GY, Liem RKHRoles of head and tail domains in α-internexin’s self-assembly and coassembly with the neurofilament triplet proteins. J Cell Science. 1998;111:321–333.[PubMed][Google Scholar]
  • 51. Lee VM-Y, Carden MJ, Schlaepfer WW, Trojanowski JQMonoclonal antibodies distinguish several differentially phosphorylated states of the two largest rat neurofilament subunits (NF-H and NF-M) and demonstrate their existence in the normal nervous system of adult rats. J Neurosci. 1987;7:3478–3488.[Google Scholar]
  • 52. Carden MJ, Trojanowski JQ, Schlaepfer WW, Lee VM-YTwo-stage expression of neurofilament polypeptides during rat neurogenesis with early establishment of adult phosphorylation patterns. J Neurosci. 1987;7:3499–3504.[Google Scholar]
  • 53. Hill WD, Lee VM-Y, Hurtig HI, Murray JM, Trojanowski JQEpitopes located in spatially separate domains of each neurofilament subunit are present in Parkinson’s disease Lewy body. J Comp Neurol. 1991;309:150–160.[PubMed][Google Scholar]
  • 54. Schmidt ML, Murray J, Lee VM-Y, Hill WD, Wertkin A, Trojanowski JQEpitope map of neurofilament protein domains in cortical and peripheral nervous system Lewy bodies. Am J Pathol. 1991;139:53–65.[Google Scholar]
  • 55. Manetto V, Sternberger NH, Perry G, Sternberger LA, Gambetti PPhosphorylation of neurofilaments is altered in amyotrophic lateral sclerosis. J Neuropathol Exp Neurol. 1988;47:642–653.[PubMed][Google Scholar]
  • 56. Leigh PN, Dodson A, Swash M, Brion JP, Anderton BHCytoskeletal abnormalities in motor neuron disease: an immunohistochemical study. Brain. 1989;112:521–535.[PubMed][Google Scholar]
  • 57. Goldstein E, Sternberger NM, Sternberger LAPhosphorylation protects neurofilaments against proteolysis. J Neuroimmunol. 1987;14:149–160.[PubMed][Google Scholar]
  • 58. Fliegner KH, Kaplan MP, Wood TL, Pintar JE, Liem RKExpression of the gene for the neuronal intermediate filament protein α-internexin coincides with the onset of neuronal differentiation in the developing rat nervous system. J Comp Neurol. 1994;342:161–173.[PubMed][Google Scholar]
  • 59. Cairns NJ, Zhukareva V, Uryu K, et al α-Internexin is present in the pathological inclusions of neuronal intermediate filament inclusion disease. Am J Pathol. 2004;164:2153–2161.[Google Scholar]
  • 60. Cairns NJ, Uryu K, Bigio E, et al α-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathol. 2004;108:213–223.[Google Scholar]
  • 61. Josephs KA, Holton JL, Rossor MN, et al Neurofilament inclusion body disease: a new proteinopathy? Brain. 2003;126:2291–2303.[PubMed][Google Scholar]
  • 62. He CZ, Hays APExpression of peripherin in ubiquinated inclusions of amyotrophic lateral sclerosis. J Neurol Sci. 2004;217:47–54.[PubMed][Google Scholar]
  • 63. Strong MJ, Strong WL, Jaffe H, Traggert B, Sopper MM, Pant HCPhosphorylation state of the native high-molecular-weight neurofilament subunit protein from cervical spinal cord in sporadic amyotrophic lateral sclerosis. J Neurochem. 2001;76:1315–1325.[PubMed][Google Scholar]
  • 64. Perez-Olle R, Leung CL, Liem RKEffects of Charcot–Marie–Tooth-linked mutations of the neurofilament light subunit on intermediate filament formation. J Cell Sci. 2002;115:4937–4946.[PubMed][Google Scholar]
  • 65. Galvin JE, Nakamura M, McIntosh TK, et al Neurofilament-rich intraneuronal inclusions exacerbate neurodegenerative sequelae of brain trauma in NFH/LacZ transgenic mice. Exp Neurol. 2000;165:77–89.[PubMed][Google Scholar]
  • 66. Ching GY, Chien C-L, Flores R, Liem RKHOverexpression of α-internexin causes abnormal neurofilamentous accumulations and motor coordination deficits in transgenic mice. J Neurosci. 1999;19:2974–2986.[Google Scholar]
  • 67. Lee MK, Marszalek JR, Cleveland DWA mutant neurofilament subunit causes massive, selective motor neuron death: implications for the pathogenesis of human motor neuron disease. Neuron. 1994;13:975–988.[PubMed][Google Scholar]
  • 68. Canete-Soler R, Silberg DG, Gershon MD, Schlaepfer WWMutation in neurofilament transgene implicates RNA processing in the pathogenesis of neurodegenerative disease. J Neurosci. 1999;19:1273–1283.[Google Scholar]
  • 69. Beaulieu JM, Julien JPPeripherin-mediated death of motor neurons rescued by overexpression of neurofilament NF-H proteins. J Neurochem. 2003;85:248–256.[PubMed][Google Scholar]
  • 70. Robertson J, Doroudchi MM, Nguyen MD, et al A neurotoxic peripherin splice variant in a mouse model of ALS. J Cell Biol. 2003;160:939–949.[Google Scholar]
  • 71. Foster NL, Wilhelmsen K, Sima AA, Jones MZ, D’Amato CJ, Gilman SFrontotemporal dementia and parkinsonism linked to chromosome 17: a consensus conference. Ann Neurol. 1997;41:706–715.[PubMed][Google Scholar]
  • 72. Spillantini MG, Murrell JR, Goedert M, Farlow MR, Klug A, Ghetti BMutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc Natl Acad Sci U S A. 1998;95:7737–7741.[Google Scholar]
  • 73. Cleveland DW, Hwo SY, Kirschner MWPurification of tau, a microtubule-associated protein that induces assembly of microtubules from purified tubulin. J Mol Biol. 1977;116:207–225.[PubMed][Google Scholar]
  • 74. Binder LI, Frankfurter A, Rebhun LIThe distribution of tau in the mammalian central nervous system. J Cell Biol. 1985;101:1371–1378.[Google Scholar]
  • 75. Shin RW, Iwaki T, Kitamoto T, Tateishi JHydrated autoclave pretreatment enhances tau immunoreactivity in formalin-fixed normal and Alzheimer’s disease brain tissues. Lab Invest. 1991;64:693–702.[PubMed][Google Scholar]
  • 76. LoPresti P, Szuchet S, Papasozomenos SC, Zinkowski RP, Binder LIFunctional implications for the microtubule-associated protein tau: localization in oligodendrocytes. Proc Natl Acad Sci U S A. 1995;92:10 369–10 373.[Google Scholar]
  • 77. Couchie D, Mavilia C, Georgieff IS, Liem RK, Shelanski ML, Nunez JPrimary structure of high molecular weight tau present in the peripheral nervous system. Proc Natl Acad Sci U S A. 1992;89:4378–4381.[Google Scholar]
  • 78. Neve RL, Harris P, Kosik KS, Kurnit DM, Donlon TAIdentification of cDNA clones for the human microtubule-associated protein tau and chromosomal localization of the genes for tau and microtubule-associated protein 2. Brain Res. 1986;387:271–280.[PubMed][Google Scholar]
  • 79. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug ACloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci U S A. 1988;85:4051–4055.[Google Scholar]
  • 80. Andreadis A, Brown WM, Kosik KSStructure and novel exons of the human tau gene. Biochemistry. 1992;31:10 626–10 633.[PubMed][Google Scholar]
  • 81. Goedert M, Spillantini MG, Jakes R, Rutherford D, Crowther RAMultiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer’s disease. Neuron. 1989;3:519–526.[PubMed][Google Scholar]
  • 82. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RACloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J. 1989;8:393–399.[Google Scholar]
  • 83. Goedert M, Jakes RExpression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J. 1990;9:4225–4230.[Google Scholar]
  • 84. Hong M, Zhukareva V, Vogelsberg-Ragaglia V, et al Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science. 1998;282:1914–1917.[PubMed][Google Scholar]
  • 85. Weingarten MD, Lockwood AH, Hwo SY, Kirschner MWA protein factor essential for microtubule assembly. Proc Natl Acad Sci U S A. 1975;72:1858–1862.[Google Scholar]
  • 86. Himmler A, Drechsel D, Kirschner MW, Martin DW., Jr Tau consists of a set of proteins with repeated C-terminal microtubule-binding domains and variable N-terminal domains. Mol Cell Biol. 1989;9:1381–1388.
  • 87. Lee G, Neve RL, Kosik KSThe microtubule binding domain of tau protein. Neuron. 1989;2:1615–1624.[PubMed][Google Scholar]
  • 88. Butner KA, Kirschner MWTau protein binds to microtubules through a flexible array of distributed weak sites. J Cell Biol. 1991;115:717–730.[Google Scholar]
  • 89. Drechsel DN, Hyman AA, Cobb MH, Kirschner MWModulation of the dynamic instability of tubulin assembly by the microtubule-associated protein tau. Mol Biol Cell. 1992;3:1141–1154.[Google Scholar]
  • 90. Yoshida H, Ihara YTau in paired helical filaments is functionally distinct from fetal tau: assembly incompetence of paired helical filament-tau. J Neurochem. 1993;61:1183–1186.[PubMed][Google Scholar]
  • 91. Bramblett GT, Goedert M, Jakes R, Merrick SE, Trojanowski JQ, Lee VMAbnormal tau phosphorylation at Ser396 in Alzheimer’s disease recapitulates development and contributes to reduced microtubule binding. Neuron. 1993;10:1089–1099.[PubMed][Google Scholar]
  • 92. Biernat J, Gustke N, Drewes G, Mandelkow EM, Mandelkow EPhosphorylation of Ser262 strongly reduces binding of tau to microtubules: distinction between PHF-like immunoreactivity and microtubule binding. Neuron. 1993;11:153–163.[PubMed][Google Scholar]
  • 93. Billingsley ML, Kincaid RLRegulated phosphorylation and dephosphorylation of tau protein: effects on microtubule interaction, intracellular trafficking and neurodegeneration. Biochem J. 1997;323:577–591.[Google Scholar]
  • 94. Buée L, Bussière T, Buée-Scherrer V, Delacourte A, Hof PRTau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev. 2000;33:1–36.[PubMed][Google Scholar]
  • 95. Hong M, Trojanowski JQ, Lee VM-Y. Tau-based neurofibrillary lesions. In: Clark CM, Trojanowski JQ, editors. Neurodegenerative Dementias. McGraw-Hill; New York: 2000. pp. 161–175. [PubMed]
  • 96. Hasegawa M, Jakes R, Crowther RA, Lee VM, Ihara Y, Goedert MCharacterization of mAb AP422, a novel phosphorylation-dependent monoclonal antibody against tau protein. FEBS Lett. 1996;384:25–30.[PubMed][Google Scholar]
  • 97. Hoffmann R, Lee VM-Y, Leight S, Varga I, Otvos L., Jr Unique Alzheimer’s disease paired helical filament specific epitopes involve double phosphorylation at specific sites. Biochemistry. 1997;36:8114–8124.[PubMed]
  • 98. Zheng-Fischhofer Q, Biernat J, Mandelkow EM, Illenberger S, Godemann R, Mandelkow ESequential phosphorylation of tau by glycogen synthase kinase-3beta and protein kinase A at Thr212 and Ser214 generates the Alzheimer-specific epitope of antibody AT100 and requires a paired-helical-filament-like conformation. Eur J Biochem. 1998;252:542–552.[PubMed][Google Scholar]
  • 99. Yasuda M, Kawamata T, Komure O, et al A mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration. Neurology. 1999;53:864–868.[PubMed][Google Scholar]
  • 100. Delisle MB, Murrell JR, Richardson R, et al A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy. Acta Neuropathol. 1999;98:62–77.[PubMed][Google Scholar]
  • 101. Varani L, Hasegawa M, Spillantini MG, et al Structure of tau exon 10 splicing regulatory element RNA and destabilization by mutations of frontotemporal dementia and parkinsonism linked to chromosome 17. Proc Natl Acad Sci U S A. 1999;96:8229–8234.[Google Scholar]
  • 102. Grover A, Houlden H, Baker M, et al 5′ splice site mutations in tau associated with the inherited dementia FTDP-17 affect a stem-loop structure that regulates alternative splicing of exon 10. J Biol Chem. 1999;274:15 134–15 143.[PubMed][Google Scholar]
  • 103. D’Souza I, Schellenberg DDeterminants of 4 repeat tau expression: coordination between enhancing and inhibitory splicing sequences for exon 10 inclusion. J Biol Chem. 2000;275:17 700–17 709.[PubMed][Google Scholar]
  • 104. Gao QS, Memmott J, Lafyatis R, Stamm S, Screaton G, Andreadis AComplex regulation of tau exon 10, whose missplicing causes frontotemporal dementia. J Neurochem. 2000;74:490–500.[PubMed][Google Scholar]
  • 105. Grover A, DeTure M, Yen SH, Hutton MEffects on splicing and protein function of three mutations in codon N296 of tau in vitro. Neurosci Lett. 2002;323:33–36.[PubMed][Google Scholar]
  • 106. Hulette CM, Pericak-Vance MA, Roses AD, et al Neuropathological features of frontotemporal dementia and parkinsonism linked to chromosome 17q21–22 (FTDP-17): Duke family 1684. J Neuropathol Exp Neurol. 1999;58:859–866.[PubMed][Google Scholar]
  • 107. Goedert M, Spillantini MG, Crowther RA, et al Tau gene mutation in familial progressive subcortical gliosis. Nature Med. 1999;5:454–457.[PubMed][Google Scholar]
  • 108. Arima K, Kowalska A, Hasegawa M, et al Two brothers with frontotemporal dementia and parkinsonism with an N279K mutation of the tau gene. Neurology. 2000;54:1787–1795.[PubMed][Google Scholar]
  • 109. Goode BL, Feinstein SCIdentification of a novel microtubule binding and assembly domain in the developmentally regulated inter-repeat region of tau. J Cell Biol. 1994;124:769–782.[Google Scholar]
  • 110. Goode BL, Denis PE, Panda D, et al Functional interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly. Mol Biol Cell. 1997;8:353–365.[Google Scholar]
  • 111. Hasegawa M, Smith MJ, Goedert MTau proteins with FTDP-17 mutations have a reduced ability to promote microtubule assembly. FEBS Lett. 1998;437:207–210.[PubMed][Google Scholar]
  • 112. Barghorn S, Zheng-Fischhofer Q, Ackmann M, et al Structure, microtubule interactions, and paired helical filament aggregation by tau mutants of frontotemporal dementias. Biochemistry. 2000;39:11 714–11 721.[PubMed][Google Scholar]
  • 113. Rizzu P, Joosse M, Ravid R, et al Mutation-dependent aggregation of tau protein and its selective depletion from the soluble fraction in brain of P301L FTDP-17 patients. Hum Mol Genet. 2000;9:3075–3082.[PubMed][Google Scholar]
  • 114. Miyasaka T, Morishima-Kawashima M, Ravid R, et al Selective deposition of mutant tau in the FTDP-17 brain affected by the P301L mutation. J Neuropathol Exp Neurol. 2001;60:872–884.[PubMed][Google Scholar]
  • 115. Arrasate M, Perez M, Armas-Portela R, Avila J. Polymerization of tau peptides into fibrillar structures. The effect of FTDP-17 mutations. FEBS Lett. 1999;446:199–202.[PubMed]
  • 116. Nacharaju P, Lewis J, Easson C, et al Accelerated filament formation from tau protein with specific FTDP-17 missense mutations. FEBS Lett. 1999;447:195–199.[PubMed][Google Scholar]
  • 117. Goedert M, Jakes R, Crowther RAEffects of frontotemporal dementia FTDP-17 mutations on heparin-induced assembly of tau filaments. FEBS Lett. 1999;450:306–311.[PubMed][Google Scholar]
  • 118. Gamblin TC, King ME, Dawson H, et al In vitro polymerization of tau protein monitored by laser light scattering: method and application to the study of FTDP-17 mutants. Biochemistry. 2000;39:6136–6144.[PubMed][Google Scholar]
  • 119. Goedert M, Satumtira S, Jakes R, et al Reduced binding of protein phosphatase 2A to tau protein with frontotemporal dementia and parkinsonism linked to chromosome 17 mutations. J Neurochem. 2000;75:2155–2162.[PubMed][Google Scholar]
  • 120. Götz J, Chen F, Barmettler R, Nitsch RMTau filament formation in transgenic mice expressing P301L tau. J Biol Chem. 2001;276:529–534.[PubMed][Google Scholar]
  • 121. Götz JTau and transgenic animal models. Brain Res Rev. 2001;35:266–286.[PubMed][Google Scholar]
  • 122. Lewis J, McGowan E, Rockwood J, et al Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein. Nature Genet. 2000;25:402–405.[PubMed][Google Scholar]
  • 123. Ishihara T, Hong M, Zhang B, et al Age-dependent emergence and progression of a tauopathy in transgenic mice overexpressing the shortest human tau isoform. Neuron. 1999;24:751–762.[PubMed][Google Scholar]
  • 124. Wittmann CW, Wszolek MF, Shulman JM, et al Tauopathy in Drosophila: neurodegeneration without neurofibrillary tangles. Science. 2001;293:711–714.[PubMed][Google Scholar]
  • 125. Jackson GR, Wiedau-Pazos M, Sang TK, et al Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron. 2002;34:509–519.[PubMed][Google Scholar]
  • 126. Kraemer BC, Zhang B, Leverenz JB, Thomas JH, Trojanowski JQ, Schellenberg GDNeurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc Natl Acad Sci U S A. 2003;100:9980–9985.[Google Scholar]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.